The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial
Abstract Multiple Sclerosis (MS) is a chronic demyelination disease of the central nervous system (CNS). The gut-brain axis involves communication between the nervous, endocrine, and immune systems. Probiotics can positively impact immune and inflammatory responses by regulating gut microbiota. A to...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-46047-6 |
| _version_ | 1797636948327661568 |
|---|---|
| author | Kimia Motlagh Asghari Neda Dolatkhah Hormoz Ayromlou Fatemeh Mirnasiri Taher Dadfar Maryam Hashemian |
| author_facet | Kimia Motlagh Asghari Neda Dolatkhah Hormoz Ayromlou Fatemeh Mirnasiri Taher Dadfar Maryam Hashemian |
| author_sort | Kimia Motlagh Asghari |
| collection | DOAJ |
| description | Abstract Multiple Sclerosis (MS) is a chronic demyelination disease of the central nervous system (CNS). The gut-brain axis involves communication between the nervous, endocrine, and immune systems. Probiotics can positively impact immune and inflammatory responses by regulating gut microbiota. A total of 40 MS patients (average age of 34.38 ± 6.65) were examined to determine the effect of the Saccharomyces boulardii supplement for four months compared to a placebo. The results showed that the Saccharomyces boulardii significantly decreased the inflammatory marker high-sensitivity C-reactive protein (hs-CRP) compared to the placebo (P < 0.001). The serum antioxidant capacity (TAC) also increased significantly in the probiotic group compared to the placebo (p = 0.004). Both the probiotic and placebo groups showed a reduction in the oxidative stress indicator malondialdehyde (MDA), but there was no significant difference between the two groups. Pain intensity (measured by Visual Analogue Scale) and fatigue severity (measured by Fatigue Severity Scale) significantly decreased in the probiotic group compared to the placebo (p = 0.004 and p = 0.01, respectively). The probiotic group experienced significant improvement in some quality of life scales (measured by 36-Item Short Form Survey) and somatic and social dysfunction subscale of General Health Questionnaire scores compared to the placebo group (p = 0.01). The study suggests that the Saccharomyces boulardii probiotic supplement may benefit inflammatory markers, oxidative stress indicators, pain, fatigue, and quality of life in MS patients. |
| first_indexed | 2024-03-11T12:42:27Z |
| format | Article |
| id | doaj.art-1846f05a3bce4a58a821be194d892f8b |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-11T12:42:27Z |
| publishDate | 2023-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-1846f05a3bce4a58a821be194d892f8b2023-11-05T12:12:11ZengNature PortfolioScientific Reports2045-23222023-10-0113111310.1038/s41598-023-46047-6The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trialKimia Motlagh Asghari0Neda Dolatkhah1Hormoz Ayromlou2Fatemeh Mirnasiri3Taher Dadfar4Maryam Hashemian5Physical Medicine and Rehabilitation Research Center, Emam Reza Hospital, Tabriz University of Medical SciencesPhysical Medicine and Rehabilitation Research Center, Emam Reza Hospital, Tabriz University of Medical SciencesFaculty of Medicine, Tabriz University of Medical SciencesFaculty of Medicine, Tabriz University of Medical SciencesFaculty of Medicine, Tabriz University of Medical SciencesDepartment of Biology, School of Arts and Sciences, Utica UniversityAbstract Multiple Sclerosis (MS) is a chronic demyelination disease of the central nervous system (CNS). The gut-brain axis involves communication between the nervous, endocrine, and immune systems. Probiotics can positively impact immune and inflammatory responses by regulating gut microbiota. A total of 40 MS patients (average age of 34.38 ± 6.65) were examined to determine the effect of the Saccharomyces boulardii supplement for four months compared to a placebo. The results showed that the Saccharomyces boulardii significantly decreased the inflammatory marker high-sensitivity C-reactive protein (hs-CRP) compared to the placebo (P < 0.001). The serum antioxidant capacity (TAC) also increased significantly in the probiotic group compared to the placebo (p = 0.004). Both the probiotic and placebo groups showed a reduction in the oxidative stress indicator malondialdehyde (MDA), but there was no significant difference between the two groups. Pain intensity (measured by Visual Analogue Scale) and fatigue severity (measured by Fatigue Severity Scale) significantly decreased in the probiotic group compared to the placebo (p = 0.004 and p = 0.01, respectively). The probiotic group experienced significant improvement in some quality of life scales (measured by 36-Item Short Form Survey) and somatic and social dysfunction subscale of General Health Questionnaire scores compared to the placebo group (p = 0.01). The study suggests that the Saccharomyces boulardii probiotic supplement may benefit inflammatory markers, oxidative stress indicators, pain, fatigue, and quality of life in MS patients.https://doi.org/10.1038/s41598-023-46047-6 |
| spellingShingle | Kimia Motlagh Asghari Neda Dolatkhah Hormoz Ayromlou Fatemeh Mirnasiri Taher Dadfar Maryam Hashemian The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial Scientific Reports |
| title | The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial |
| title_full | The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial |
| title_fullStr | The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial |
| title_full_unstemmed | The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial |
| title_short | The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial |
| title_sort | effect of probiotic supplementation on the clinical and para clinical findings of multiple sclerosis a randomized clinical trial |
| url | https://doi.org/10.1038/s41598-023-46047-6 |
| work_keys_str_mv | AT kimiamotlaghasghari theeffectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT nedadolatkhah theeffectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT hormozayromlou theeffectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT fatemehmirnasiri theeffectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT taherdadfar theeffectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT maryamhashemian theeffectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT kimiamotlaghasghari effectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT nedadolatkhah effectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT hormozayromlou effectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT fatemehmirnasiri effectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT taherdadfar effectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial AT maryamhashemian effectofprobioticsupplementationontheclinicalandparaclinicalfindingsofmultiplesclerosisarandomizedclinicaltrial |